Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Novo’s Ozempic Skips Listing for 3rd Time 8 Months after Approval
Novo Nordisk’s once-weekly GLP-1 agent Ozempic (semaglutide) is skipping its NHI price listing for the third time since its approval in March, with its name not found on the slate of new drugs approved on November 14 for an upcoming…
To read the full story
Related Article
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
- Novo to Develop New Dosages for Ozempic, 14-Day Prescription Limit Weighs
November 16, 2018
- Chuikyo OKs Listing of Astellas’ AML Med, Lilly’s Verzenio and More on Nov. 20
November 14, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- MHLW Approves Hemlibra, Shingrix, Ozempic, and More
March 26, 2018
- MHLW Panel Backs Novo’s Semaglutide after Recommendation Hold
January 29, 2018
- Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
REGULATORY
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
- Yaz, Actemra Indications Deemed High-Need by MHLW Panel
September 7, 2026
- Minister Defends Scope of Low-Income Exemption for OTC-Like Drug Charge
September 7, 2026
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…